AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02049437 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: tocilizumab
Description: Subjects will be randomized 1:1 to one of the following arms:~ARM A: TCZ, 4 mg/Kg by IV infusion over 60 minutes (not to exceed 400 mg) once at study entry, followed by TCZ, 8 mg/Kg by IV infusion over 60 minutes (not to exceed 800 mg) at weeks 4 and 8, and THEN placebo by IV infusion at weeks 20, 24, and 28.~ARM B: Placebo by IV infusion at study entry followed by placebo by IV infusion at weeks 4 and 8, and THEN TCZ, 4 mg/Kg (not to exceed 400 mg) by IV infusion over 60 minutes once at week 20, followed by TCZ, 8 mg/Kg (not to exceed 800 mg) by IV infusion over 60 minutes at weeks 24 and 28.
Study NCT02049437 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Subjects will be randomized 1:1 to one of the following arms:~ARM A: TCZ, 4 mg/Kg by IV infusion over 60 minutes (not to exceed 400 mg) once at study entry, followed by TCZ, 8 mg/Kg by IV infusion over 60 minutes (not to exceed 800 mg) at weeks 4 aned 8, and THEN placebo by IV infusion at weeks 20, 24, and 28.~ARM B: Placebo by IV infusion at study entry followed by placebo by IV infusion at weeks 4 and 8, and THEN TCZ, 4 mg/Kg (not to exceed 400 mg) by IV infusion over 60 minutes once at week 20, followed by TCZ, 8 mg/Kg (not to exceed 800 mg) by IV infusion over 60 minutes at weeks 24 and 28.
Study NCT02049437 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will be randomized 1:1 to one of the following arms:~ARM A: TCZ, 4 mg/Kg by IV infusion over 60 minutes (not to exceed 400 mg) once at study entry, followed by TCZ, 8 mg/Kg by IV infusion over 60 minutes (not to exceed 800 mg) at weeks 4 aned 8, and THEN placebo by IV infusion at weeks 20, 24, and 28.~ARM B: Placebo by IV infusion at study entry followed by placebo by IV infusion at weeks 4 and 8, and THEN TCZ, 4 mg/Kg (not to exceed 400 mg) by IV infusion over 60 minutes once at week 20, followed by TCZ, 8 mg/Kg (not to exceed 800 mg) by IV infusion over 60 minutes at weeks 24 and 28.
Study NCT00740519 — intervention group
Intervention type: DRUG
Intervention: insulin detemir
Description: Start dose and frequency to be prescribed by the physician as a result of a normal clinical evaluation.
Study NCT02831400 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Walking test
Description: Walking test to increase cardiac output, maximum 12 minutes
Study NCT02831400 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Meal
Description: After the walking test, volunteers eat a standard warm meal
Study NCT04144985 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Visual analog scale (VAS) of pain to evaluate the discomfort participants experience.
Description: Eyelid retraction was performed with one of the three methods (eyelid speculum, unimanual eyelid retraction or cotton tipped applicator assisted eyelid retraction) and participants were then asked to rate their discomfort during the procedure with a visual analog scale (VAS) of pain.
Study NCT04491734 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: maltosyl-isomalto-oligosaccharides (MIMO)
Description: Digestion-resistant carbohydrate, ISOT-101, a specific formulation of maltosyl-isomalto-oligosaccharides (MIMO), that serves as a prebiotic, feeding selected bacteria that commonly inhabit the human GI tract.
Study NCT03231345 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: US guided IJ
Description: IV catheter placement
Study NCT04144985 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Visual analog scale (VAS) of pain to evaluate the discomfort participants experience.
Description: Eyelid retraction was performed with one of the three methods (eyelid speculum, unimanual eyelid retraction or cotton tipped applicator assisted eyelid retraction) and participants were then asked to rate their discomfort during the procedure with a visual analog scale (VAS) of pain.
Study NCT03950908 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Single bite biopsy technique
Description: During biopsy collection one specimen will be retrieved during a single passage of the biopsy forceps.
Study NCT03950908 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Double bite biopsy technique
Description: During biopsy collection two specimens will be retrieved during a single passage of the biopsy forceps.
Study NCT04135924 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitation
Description: physical exercise and respiratory muscle training
Study NCT03207425 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EDP 305
Description: Each subject will receive a single dose of EDP 305 on Day 1.
Study NCT03424928 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide 4 MG Oral Capsule
Description: per os,capsule,4mg,1 capsule per period
Study NCT03424928 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide 4 MG Oral Capsule-Pomalyst
Description: per os,capsule,4mg,1 capsule per period
Study NCT01822678 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eslicarbazepine Acetate
Description: Eslicarbazepine Acetate, starting with 800 mg per day and up-titrated in 800 mg steps until 2400 mg (maximum dose) according to clinical response.
Study NCT01822678 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eslicarbazepine Acetate
Description: Eslicarbazepine Acetate, starting with 600 mg per day and up-titrated in 600 mg steps until 1800 mg (maximum dose) according to clinical response.
Study NCT01822678 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT01905410 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VVZ-149 Injection
Description: VVZ-149 in water for injection
Study NCT03231345 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: Ultrasound-guided Internal Jugular vein
Study NCT03439995 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Open lung protective ventilation
Description: Higher PEEP, lower tidal volume mechanical ventilation
Study NCT03439995 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional ventilation
Description: Lower PEEP, standard tidal volume mechanical ventilation
Study NCT04592653 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nemvaleukin alfa
Description: IV infusion over 30 minutes
Study NCT04592653 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion over 30 minutes
Study NCT01905410 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: water for injection
Study NCT04041375 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iNSPiRED
Description: The peer intervention will include approximately 5 to 6 contacts over a 3-month period. Peer navigators are responsible for providing emotional and social support, normalizing the difficulty of living with DM, modeling help-seeking behaviors, and connecting patients with VHA and/or CBOs to address mental health and DM self-management needs. Peer coaches are not responsible for health education directly; rather, they encourage patients to use appropriate programs in which mental health and DM self-management services are provided.
Study NCT04041375 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Veterans randomized to the usual care condition will be encouraged to follow-up with their primary care provider and/or specialty providers for management of their health conditions. They will also receive a packet of printed information that includes a list of self-management support resources in the VHA and the local community. They will receive no further specific recommendations
Study NCT04203381 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: GnRH Agonist
Description: Forty participants who are transgender and who have been prescribed a gonadotropin-releasing hormone (GnRH) agonist by their physician will undergo magnetic resonance imaging (MRI), magnetic resonance spectroscopy (MRS), dual-energy x-ray absorptiometry (DXA) and peripheral quantitative computed tomography (pQCT) scans at baseline, at 12 months and at 24 months after initiation of the GnRH agonist therapy. This longitudinal observational study of two cohorts seeks to identify significant changes in bone marrow adiposity and bone density over 24 months. The same assessments will be obtained in 40 healthy control subjects matched for age, race/ethnicity and body mass index, all factors that are known to influence skeletal outcomes. The evaluations of bone marrow adiposity will be correlated with bone density measurements and the assessments of mood (validated anxiety and depression scales) and health-related quality of life, before and after pubertal blockade.
Study NCT00985816 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lactobacillus Reuteri
Description: L. reuteri DSM 17938 will be given at a dose of 1x108 colony forming units (CFU)/day
Study NCT00985816 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT00943124 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK0524B (ER niacin (+) laropiprant (+) simvastatin)
Description: Single dose of MK0524B (ER niacin 900 mg/ laropiprant 20 mg/ simvastatin 20 mg) in one of two treatment periods.
Study NCT00943124 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK0524A (ER niacin + laropiprant)
Description: Single dose of MK0524A (ER niacin 1000 mg/ laropiprant 20 mg) in one of two treatment periods.
Study NCT00943124 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: Single dose simvastatin (Zocor™) 20 mg in one of two treatment periods.
Study NCT02071927 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CB-839
Description: Single-agent CB-839
Study NCT02071927 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CB-Aza
Description: CB-839 in combination with standard dose azacitidine
Study NCT04680156 — intervention group
Intervention type: DRUG
Intervention: Previously treated with EN3835 up to 1.74 mg or Placebo in EN3835-210 or the pivotal phase 3 studies
Description: No treatment to be administered - Observational only
Study NCT03536897 — intervention group
Intervention type: RADIATION
Intervention: IORT
Description: Intraoperative radiation therapy with INTRABEAM system to a dose of 20 Gy
Study NCT01663168 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifabutin
Study NCT01663168 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifabutin
Study NCT04911413 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Description: The drug used in this RCT is tranexamic acid. We used three different doses of TXA in three groups.
Study NCT02185755 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Internet-Based Glucose Monitoring System
Study NCT00024258 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: arsenic trioxide
Study NCT00111137 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rHuEPO
Description: rHuEPO 40,000U QW for 4 weeks. Dose will be increased to 60,000U/week at week 5 if inadequate response through week 12.
Study NCT00111137 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa
Description: 4.5 mcg/kg QW for 4 weeks then Q3W starting at week 5 through week 11.
Study NCT02902055 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neuromuscular Blocking Agents
Description: Neuromuscular blockae
Study NCT02902055 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isotonic saline
Description: Placebo
Study NCT03493035 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Computed tomography angiography (3D CTA)
Description: CTA scans data in DICOM format was used to morphometric analysis of aneurysmal and non-aneurysmal MCA bifurcations.
Study NCT03493035 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Transcranial color-coded sonography (TCCS)
Description: TCCS was used to assess of hemodynamic parameters of aneurysmal and non-aneurysmal MCA bifurcations.
Study NCT03693833 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol
Description: Cannabidiol (CBD) tablets of 10mg each
Study NCT03693833 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Oral Placebo tablets of 10mg each
Study NCT00506012 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T2000
Description: T2000 at doses of 200 mg a day to 1000 mg a day
Study NCT03294317 — intervention group
Intervention type: DEVICE
Intervention: His bundle pacing
Description: Medtronic SelectSecure SureScan MRI model 3830 lead
Study NCT03545399 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ulva Lactuca
Description: The dose was taken with a glass of water during the evening meal once daily
Study NCT04541225 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NUV-422
Description: NUV-422 is an investigational drug for oral dosing.
Study NCT03281564 — intervention group
Intervention type: OTHER
Intervention: Quality of life after Essure® removal
Description: Questionnaire to assess the quality of life 1, 3, 6 and 12 months after laparoscopic removal of Essure® device
Study NCT00335556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given IV
Study NCT02185755 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Normal Medication Positive Control
Study NCT03464461 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ketorolac
Description: IV drug
Study NCT03464461 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac
Description: IV drug
Study NCT01087697 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neo-Urinary Conduit
Description: Implantation with the autologous Neo-Urinary Conduit
Study NCT01509508 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immediate ARV treatment initiation with TDF/FTC/EFV
Description: All HIV-infected adults will be offered ART regardless of their immunological and clinical staging.~The first line regimen proposed will be Atripla (R), a fixed dose combination containing tenofovir disoproxil (245 mg)/emtricitabine (200 mg)/efavirenz (600 mg)(FTC/TDF/EFV). The dosing will be 1 tablet OD.
Study NCT03545399 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The dose was taken with a glass of water during the evening meal once daily
Study NCT02922582 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DepoTXA
Study NCT02922582 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid
Study NCT02571634 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Lazanda
Description: Given pre radiofrequency ablation of the lumbar facet joints to see if patients can remain alert, and it provides relaxation and pain control.
Study NCT03680716 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine injection
Description: Saphenous nerve block with 20ml of ropivacaine 0.5% and IPACK block with 30ml of ropivacaine 0.2% (total dose of 160 mg).
Study NCT03680716 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine injection
Description: Periarticular infiltration of 80 ml ropivacaine 0.2% (total dose of 160mg).
Study NCT01134991 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Topical Minocycline Foam FXFM244
Description: FXFM244 - 1%, FXFM244 - 4% or Placebo to be applied twice daily during 12 weeks
Study NCT01509508 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: South African recommendation guided ARV (TDF/FTC/EFV) initiation
Description: HIV-infected adult participants will be eligible for ART as per the South African guidelines (August 2011) if:~* CD4 count ≤ 350 cells/mm3 irrespective of clinical symptoms~* WHO clinical stage 3 or 4 irrespective of CD4 count~* MDR or XDR TB The first line regimen proposed will be Atripla (R), a fixes dose combination containing tenofovir disoproxil (245 mg)/emtricitabine (200 mg)/efavirenz (600 mg)(TDF/FTC/EFV). The dosing will be 1 tablet OD.
Study NCT01134991 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical Minocycline Foam FXFM244
Description: FXFM244 - 1%, FXFM244 - 4% or Placebo to be applied twice daily during 12 weeks
Study NCT03879486 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intrarectal povidone-iodine cleansing plus formalin disinfection of needle tip during transrectal ultrasound guided prostate biopsy
Description: The examiner will use a gauze soaked and saturated with iodopovidone and perform a mechanical friction motion on the anterior wall of the rectum, at least 5 times from one margin to another of the prostate laterally-laterally. A period of two (2) minutes shall be waited from the prophylactic cleaning of the rectum to the beginning of the biopsy. The examiner will use a technique of disinfecting the 10% formaldehyde biopsy needle without manual contact by soaking the distal 3 cm of the needle directly into a vial containing the bactericidal solution between obtaining the different fragments. An individual bottle will be used for each patient
Study NCT00777855 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: warfarin plus rifampin
Description: warfarin 7.5mg po x 1; rifampin 600mg IV x 1
Study NCT00777855 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: warfarin
Description: warfarin 7.5mg po x 1
Study NCT02473393 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPS-2071 tablet
Study NCT02938845 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Spielberger's State-Trait Anxiety Inventory(STAI )
Description: State anxiety (STAI-S) refers to a temporary emotional state related to a specific situation, whereas trait anxiety (STAI-T) represents anxiety as a relatively stable personality character. Each scale has values ranging from 20 to 80, with higher scores representing more severe anxiety. The STAI has no established categories, but a cutoff score of 40 has been used to identify patients with high/very high anxiety. The validity and reliability of the Turkish versions of these instruments have been validated.
Study NCT02938845 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: total laparoscopic hysterectomy(TLH)
Study NCT03046472 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Therapy treatment for Postural Behavior
Description: Physical Therapy treatment for Postural Behavior: intervention program will include physical awareness by using a mirror and practice for good posture, and exercises for flexibility, strength and muscle endurance.~All participants will get 10-15 minutes of exercise for performing every day.
Study NCT03046472 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical Therapy treatment for Postural Behavior
Description: Physical Therapy treatment for Postural Behavior: intervention program will include physical awareness by using a mirror and practice for good posture, and exercises for flexibility, strength and muscle endurance.~All participants will get 10-15 minutes of exercise for performing every day.
Study NCT01467596 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Elderly population, Middle aged population
Description: The study method is a step-up/step-down sequence model where the dose of local anesthetic for the following patient is determined by the outcome of the preceding block. The starting dose of 50:50 mixture of 0.5% levobupivacaine and 2% lidocaine is 30 mL. In the case of block failure, the dose will be increased by 5 mL. Conversely, block success will result in a reduction in dose by 5 mL. A blinded assistant will assess sensory and motor blockade in each nerve territory ( the median, radial, ulnar and musculocutaneous) at 5-min intervals up to 30 min after completion of US-SCB. Effective US-SCB will be defined as complete sensory blockade in the distribution of the radial, ulnar, median and musculocutaneous nerve.
Study NCT01467596 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Elderly population, Middle aged population
Description: The study method is a step-up/step-down sequence model where the dose of local anesthetic for the following patient is determined by the outcome of the preceding block. The starting dose of 50:50 mixture of 0.5% levobupivacaine and 2% lidocaine is 30 mL. In the case of block failure, the dose will be increased by 5 mL. Conversely, block success will result in a reduction in dose by 5 mL. A blinded assistant will assess sensory and motor blockade in each nerve territory ( the median, radial, ulnar and musculocutaneous) at 5-min intervals up to 30 min after completion of US-SCB. Effective US-SCB will be defined as complete sensory blockade in the distribution of the radial, ulnar, median and musculocutaneous nerve.
Study NCT04006873 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tezacaftor/Ivacaftor + Ivacaftor
Description: As per description in arms.
Study NCT04006873 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: As per description in arms
Study NCT01546727 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Family Intervention
Description: Three months of weekly treatment delivered via alternating group based clinic visits and individual home visits followed by three months of every other week treatment alternating between clinic and home.
Study NCT02938845 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: total abdominal hysterectomy(TAH)
Study NCT02378675 — intervention group
Intervention type: OTHER
Intervention: Blood draw
Description: During the routine blood sampling, a 10ml plasma sample as well as a 10ml serum sample will be obtained, spinned and stored at -80°C until the final assessment of adipocytokines.